Overview

Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy

Status:
Unknown status
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
Evaluation of ranibizumab on the ease and procedure and complication in proliferative diabetic retinopathy (PDR) requiring vitrectomy.
Phase:
Phase 3
Details
Lead Sponsor:
Retina Associates, Kansas City
Collaborator:
Genentech, Inc.
Treatments:
Ranibizumab